Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 15/20 | 0.68 |
| ▸ | EPAS1 | Q99814 | 15/20 | 0.68 |
| ▸ | EP300 | Q09472 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14178660 | 0.86 | HIF1A (0.63) | HIF1AEPAS1 | |
| SCHEMBL2557901 | 0.86 | HIF1A (0.52) | HIF1AEPAS1PARP1 | |
| SCHEMBL2564588 | 0.85 | HIF1A (0.62) | HIF1AEPAS1 | |
| SCHEMBL2560898 | 0.82 | HIF1A (0.63) | HIF1AEPAS1EP300 | |
| SCHEMBL2564537 | 0.82 | HIF1A (0.66) | HIF1AEPAS1EP300 | |
| SCHEMBL14930293 | 0.81 | HIF1A (0.61) | HIF1AEPAS1 | |
| SCHEMBL2564276 | 0.80 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL14541294 | 0.80 | HIF1A (0.56) | HIF1AEPAS1EP300 | |
| SCHEMBL2564127 | 0.78 | HIF1A (0.49) | HIF1AEPAS1 | |
| SCHEMBL2564356 | 0.78 | HIF1A (0.49) | HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062072-B2 | Inhibitors of HIF and angiogenesis | EMORY UNIVERSITY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2011133659-A2 | INHIBITORS OF HIF AND ANGIOGENESIS | EMORY UNIVERSITY (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | HIF1AN, HIF1A, EGLN2 | HIF1A 2/4885EPAS1 16/4885EP300 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.